New Knee Osteoarthritis Treatment to Be Discussed
Executives will discuss a potential new injectable therapy that is currently under regulatory review in the UK and EU.
Updated on Oct. 29, 2026 in Arthritis
Live Poll
Do you believe everyday patients should be able to formally influence the medical drug approval process?
Executives from San Diego-based Biosplice will discuss their investigational knee osteoarthritis treatment, lorecivivint, on a television segment scheduled for November 1, 2026. This potential therapy is currently undergoing regulatory review in the United Kingdom and the European Union.
Why it matters
Osteoarthritis affects 25 million U.S. adults with knee involvement, representing a significant burden of chronic pain and mobility loss. As new treatment modalities move through global regulatory pipelines, the field faces ongoing questions regarding long-term efficacy and safety for the millions affected.
Lorecivivint has undergone 11 clinical trials over more than a decade of research. While the treatment is under active regulatory review in the UK and EU, the specific clinical results from this development cycle remain subject to ongoing analysis.
The players
Biosplice
A San Diego-based biotechnology company developing kinase inhibitors for osteoarthritis treatment.
Erich Horsley
An executive at Biosplice involved in the company's clinical development strategy.
Yusuf Yazici
An executive at Biosplice focused on the oversight of potential osteoarthritis therapies.
The details
Lorecivivint is designed as a small-molecule inhibitor of CLK and DYRK kinases, specifically targeting DYRK1A and CLK2. The treatment is administered via injection directly into the knee joint, with a frequency of one to two times per year. This localized approach aims to address the underlying disease process within the joint tissue rather than solely managing symptoms.
Timeline
2011: Biosplice identified the novel compound.
August 28, 2026: MHRA validated the lorecivivint application.
September 30, 2026: EMA validated the lorecivivint marketing authorization application.
November 1, 2026: Biosplice executives appear on television segment.
Health Landscape
The clinical development of lorecivivint represents a potential shift in the standard of care for knee osteoarthritis, following years of limited pharmacological innovation for the condition. This development marks a transition toward potentially disease-modifying treatments for the condition.
For adults managing knee osteoarthritis, keeping track of regulatory updates is a way to stay informed about future care options. Any questions about the potential role of new injectable treatments in your personal care plan are best directed to your primary care physician or rheumatologist.
The takeaway
Ongoing research into kinase inhibitors may eventually provide new options for managing knee joint health. Patients should continue to monitor their symptoms and discuss the evolving landscape of osteoarthritis treatments with their healthcare providers during routine checkups.
Further reading
Learn more about the latest research and standard care options in the Arthritis section.
More information
Find additional resources and advocacy updates on the osteoarthritis patient information and advocacy portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe everyday patients should be able to formally influence the medical drug approval process?
